Conceptualization: Cheryl A. London. Data curation: Katherine Dittrich, Heather L. Gardner, Jillian M. Richmond, Cheryl A. London. Formal analysis: Katherine Dittrich, Heather L. Gardner, Jillian M. Richmond ... . Funding acquisition: Cheryl A. London. Investigation: Katherine Dittrich, U¨mmu¨gu¨lsu¨m Yıldız-Altay, Fatima Qutab, Danny A. Kwong, Heather L. Gardner, Jillian M. Richmond, Cheryl A. London. Methodology
study. Author Contributions Conceptualization: Cheryl A. London. Data curation: Kate Megquier, Heather L. Gardner. Formal analysis: Kate Megquier, Kathleen Morrill, Xue Li, Heather L. Gardner. Funding ... acquisition: Cheryl A. London. Methodology: Kate Megquier, Jason Turner-Maier. Resources: Jeremy Johnson. Supervision: Elinor K. Karlsson. Visualization: Kate Megquier, Heather L. Gardner. Writing
• Google Scholar Search for Heather L. Gardner in:PubMed • Google Scholar Search for Lisa G. Barber in:PubMed • Google Scholar Search for Abbey Sadowski in:PubMed • Google Scholar Search for Cheryl A
Hyperthermia is an established anti-cancer treatment but is limited by tolerance of adjacent normal tissues. Parenteral administration of gold nanorods (NRs) as a photosensitizer amplifies the effects of hyperthermia treatment while sparing normal tissues. This therapy is well tolerated and has demonstrated anti-tumor effects in mouse models. The purpose of this phase 1 study was...
Conceptualization: Kumar V. Penmetsa, Srikant Viswanadha, Swaroop Vakkalanka, Cheryl A. London. Data curation: Heather L. Gardner, Sarah B. Rippy, Srikant Viswanadha, Cheryl A. London. Formal analysis: Heather L ... draft: Heather L. Gardner, Cheryl A. London. Writing ? review & editing: Heather L. Gardner, Kumar V. Penmetsa, Srikant Viswanadha, Cheryl A. London. 14 / 17 15 / 17 16 / 17 1. Kawauchi K , Ogasawara T
combining KPT-335 with cytotoxic chemotherapeutic agents in canine lymphoma. Notes Abbey R. Sadowski and Heather L. Gardner contributed equally to this work. Abbreviations AE: Adverse event AML
Effective therapies for transitional cell carcinoma (TCC) are limited, with objective response rates to most chemotherapeutic regimens below 20%. The purpose of this study was to investigate the biologic activity of combined toceranib phosphate and vinblastine chemotherapy for treatment of TCC. A secondary objective was to compare the utility of Computed Tomography (CT) and...
: Ryan Roberts, Hakan Cam, Amy K. LeBlanc, Jiayuh Lin, Denis C. Guttridge, Mitch A. Phelps, Peter Houghton, Cheryl A. London. Visualization: Peter Y. Yu, Heather L. Gardner. Writing ± original draft ... : Peter Y. Yu, Heather L. Gardner. Writing ± review & editing: Peter Y. Yu, Heather L. Gardner, Denis C. Guttridge, Xiaokui Mo, Peter Houghton, Cheryl A. London. 16 / 18 17 / 18 1. Arndt CA , Rose PS
Spenic hemangiosarcoma (HSA) in dogs treated with surgery alone is associated with short survival times, and the addition of doxorubicin (DOX) chemotherapy only modestly improves outcome. The purpose of this study was to evaluate the impact of toceranib administration on progression free survival in dogs with stage I or II HSA following splenectomy and single agent DOX...
Acalabrutinib (ACP-196) is a second-generation inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK) with increased target selectivity and potency compared to ibrutinib. In this study, we evaluated acalabrutinib in spontaneously occurring canine lymphoma, a model of B-cell malignancy similar to human diffuse large B-cell lymphoma (DLBCL). First, we demonstrated that...
Background We hypothesized that the addition of toceranib to metronomic cyclophosphamide/piroxicam therapy would significantly improve disease-free interval (DFI) and overall survival (OS) in dogs with appendicular osteosarcoma (OSA) following amputation and carboplatin chemotherapy. Methods and Findings This was a randomized, prospective clinical trial in which dogs with OSA...
